ART4 and neoplasm: Indeed, using the “matrisome” approach developed by R. Hynes and A. Naba (http://matrisomeproject.mit.edu), we show that pharmacologic FAK inhibition in primary CAFs isolated from patient tumours globally decreases the expression of ECM proteins from the “core matrisome” (collagens, glycoproteins and proteoglycans) and ECM regulators.